Phase 1 data indicate invikafusp alfa's potential as a precision cancer immunotherapeutic in solid tumors that have ...
Panelists discuss how to help patients weigh the risks and benefits of different treatment options for paroxysmal nocturnal hemoglobinuria (PNH), outlining tools and techniques used to ensure that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback